Oncogenic transcription factors: Cornerstones of inflammation-linked pancreatic carcinogenesis

Gut

Volumn 62, Issue 2, 2013, Pages 310-316

  Baumgart, Sandra ^a   Ellenrieder, Volker ^a   Fernandez Zapico, Martin E ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCINEURIN; CARCINOGEN; CELECOXIB; CURCUMIN; CYCLOSPORIN A; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; ISOFLAVONE; MESSENGER RNA; PACLITAXEL; PROTEIN TYROSINE KINASE; QUERCETIN; SARACATINIB; STAT3 PROTEIN; TACROLIMUS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; EPIGENETICS; GENE EXPRESSION; HUMAN; INFLAMMATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR PROMOTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84872065981     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301008     Document Type: Review

References (65)

1. Löhr M, Klöppel G, Maisonneuve P, et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23. (Pubitemid 40209467)
2. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50. (Pubitemid 38050041)
3. Morris JP 4th, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.
4. Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291-302. (Pubitemid 46349841)
5. Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 2010;32:128-31.
6. Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 2009;9:411-18.
7. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008;36:225-35. (Pubitemid 351440925)
8. Billadeau DD. Primers on molecular pathways. The glycogen synthase kinase-3beta. Pancreatology 2007;7:398-402. (Pubitemid 47587617)
9. Algül H, Adler G, Schmid RM. NF-kappaB/Rel transcriptional pathway: implications in pancreatic cancer. Int J Gastrointest Cancer 2002;31:71-8. (Pubitemid 36330108)
10. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
11. Maier HJ, Schmidt-Strassburger U, Huber MA, et al. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 2010;295:214-28.
12. Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010;291:90-8.
13. Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-63. (Pubitemid 35408327)
14. Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009;10:1314-19.
15. He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68.
16. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
18. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
19. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010;20:65-71.
20. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
21. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009;15:79-80.
22. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69.
23. Fukuda A, Wang SC, Morris JP 4th, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011;19:441-55.
24. Lagnuas L, Clipstone NA. Deregulated NFATc1 activity transforms murine fibroblasts via an autocrine growth factor-mediated Stat3-dependent pathway. J Cell Biochem 2009;108:237-48.
25. Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol 2004;36:1166-70. (Pubitemid 38515658)
26. König A, Fernandez-Zapico ME, Ellenrieder V. Primers on molecular pathways - the NFAT transcription pathway in pancreatic cancer. Pancreatology 2010;10:416-22.
27. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2010;9:810-20.
28. Müller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010;10:645-56.
29. Buchholz M, Schatz A, Wagner M, et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 2006;25:3714-24. (Pubitemid 44264881)
30. König A, Linhart T, Schlengemann K, et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastronenterology 2010;138:1189-99.
31. Saqui-Salces M, Merchant JL. Hedgehog signaling and gastrointestinal cancer. Biochim Biophys Acta 2010;1803:786-95.
32. Stecca B, Ruiz I Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2010;2:84-95.
33. Elsawa SF, Almada LL, Ziesmer SC, et al. GLI2 mediates cytokine crosstalk in the tumor microenvironment. J Biol Chem 2011;286:21524-34.
34. Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011;32:445-51.
35. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6. (Pubitemid 37355945)
36. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res 2009;69:6007-10.
37. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009;106:4254-9.
38. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
39. Nolan-Stevaux O, Lau J, Truitt ML, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009;23:24-36.
40. Ji Z, Mei FC, Xie J, et al. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007;282:14048-55. (Pubitemid 47100411)
41. Pasca di Magliano M, Sekine S, Ermilov A, et al. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006;20:3161-73. (Pubitemid 44790630)
42. Dennler S, André J, Alexaki I, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007;67:6981-6. (Pubitemid 47105546)
43. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:725-7.
44. Lionetto R, Pugliese V, Bruzzi P, et al. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995;31A:882-7.
45. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
46. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
47. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31. (Pubitemid 41282806)
48. Jutooru I, Chadalapaka G, Lei P, et al. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 2010;285 :25332-44.
49. Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 2010;98:761-9.
50. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-8.
51. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-72. (Pubitemid 41377399)
52. Liby KT, Royce DB, Risingsong R, et al. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010;3:1427-34.
53. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999;274:27307-14.
54. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010;59:630-7.
55. Sclabas GM, Uwagawa T, Schmidt C, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005;103:2485-90. (Pubitemid 40800526)
56. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003;29(Suppl 1):41-8.
57. Qiu Z, Huang C, Sun J, et al. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci 2007;98:1099-106. (Pubitemid 46865397)
58. Rajeshkumar NV, Tan AC, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009;15:4138-46.
59. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011;17:483-93.
60. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-81. (Pubitemid 40490111)
61. Wilson W 3rd, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008;68:8156-63.
62. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010;31:24-31.
63. Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57:1420-30.
64. Kasperczyk H, Baumann B, Debatin KM, et al. Characterization of sonic hedgehog as a novel NF-kB target gene that promotes NF-kB mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23:21-33.
65. Arlt A, Gehrz A, Müerköster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51. (Pubitemid 36712936)